New Agent Shows Early Promise in Triple-Class Refractory MM New Agent Shows Early Promise in Triple-Class Refractory MM

With linvoseltamab and other bispecific antibodies inducing deep and durable responses, there might finally be a go-to option for multiple myeloma patients resistant to mainstay treatments.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news